Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: The general results of combining irinotecan and platin-based chemotherapies have
been very encouraging. As the toxicity profile associated with carboplatin is preferable over
cisplatin it is our expectation that patients and physicians would prefer to use this
combination if it is equally or more efficacious. To date there has been no agreement
regarding the optimal combination of these agents. Based on the trials described in the
protocol and our experience with carboplatin/irinotecan in the treatment of non-small cell
lung cancer the present trial will utilize a 21-day cycle of irinotecan 50 mg/m2 given on
days 1 and 8 and carboplatin AUC 5 (based on the Calvert formula) on day 1.
PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin
works as first-line therapy in treating patients with extensive-stage small cell lung cancer.